Tags

Type your tag names separated by a space and hit enter

Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I.
Technol Cancer Res Treat 2015; 14(1):61-9TC

Abstract

The objective of this study is to explore the feasibility of radioiodine treatment for cervical cancer using the early growth response (Egr-1) promoter to control sodium-iodine symporter (hNIS) gene expression. The hNIS gene was previously transfected into Hela cells under the control of either the cytomegalovirus (CMV) or Egr-1 promoters. Na(125)I uptake was measured in the presence or absence of NaClO4. Na(125)I efflux was measured. The effects of external beam radiation on iodine uptake and retention were studied. The cytotoxic effects of (131)I were measured by clonogenic assay. The Na(125)I biodistribution was obtained using mice bearing control and transfected cells. The %ID/g of tumor and major organs were obtained for a range of times up to 48 hours post injection and the ratio of tumor to non-tumor activity (T/NT) was calculated. Tumors were imaged with Na(131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was calculated. Na(125)I uptake in Hela cells was minimal in the absence of hNIS. Uptake in the transfected cells was strong, and could be blocked by NaClO4. The iodine uptake of Hela-Egr-1-hNIS cells increased after the irradiation, and the magnitude of this effect approximately matched the radiation dose delivered. The efflux of 125I was affected by neither the promoter sequence nor pre-irradiation. (131)I reduced the clonogenic survival of symporter expressing cells, relative to the parental line. The effect was greatest in cells where hNIS was driven by the CMV promoter. Tumors formed from Hela-Egr-1-hNIS concentrated Na(125)I over a 12 hour period, in contrast to untransfected cells. These tumors could also be successfully imaged using either Na(131)I or (99m)TcO4 (-). (131)I uptake peaked at 4h, while (99m)TcO4 (-) accumulated over approximately 20 hours. In vivo uptake of (131)I and (99m)TcO4 (-) was slightly higher in cells transfected with the Egr-1 promoter, compared to CMV. Hela-Egr-1-hNIS cells demonstrate highly enhanced iodine uptake, and this effect is further augmented by radiation, creating a positive feedback loop which may bolster radionuclide therapy in vivo.

Authors+Show Affiliations

Department of Nuclear Medicine, the 2 Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R. China Jun Tang and Xiaoxia Wang contributed equally to this paper. drtaungjun@aliyun.com.Department of Oncology, the 2 Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R. China.Department of Nuclear Medicine, the 2 Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R. China.Department of Nuclear Medicine, the 2 Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R. China.Department of Nuclear Medicine, the 2 Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R. China.Department of Nuclear Medicine, the 2 Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, P.R. China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24354753

Citation

Tang, Jun, et al. "Sodium-iodine Symporter Gene Expression Controlled By the EGR-1 Promoter: Biodistribution, Imaging and in Vitro Radionuclide Therapy With Na(131)I." Technology in Cancer Research & Treatment, vol. 14, no. 1, 2015, pp. 61-9.
Tang J, Wang X, Xu Y, et al. Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I. Technol Cancer Res Treat. 2015;14(1):61-9.
Tang, J., Wang, X., Xu, Y., Shi, Y., Liu, Z., & Yang, Y. (2015). Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I. Technology in Cancer Research & Treatment, 14(1), pp. 61-9. doi:10.7785/tcrt.2012.500396.
Tang J, et al. Sodium-iodine Symporter Gene Expression Controlled By the EGR-1 Promoter: Biodistribution, Imaging and in Vitro Radionuclide Therapy With Na(131)I. Technol Cancer Res Treat. 2015;14(1):61-9. PubMed PMID: 24354753.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I. AU - Tang,Jun, AU - Wang,Xiaoxia, AU - Xu,Yuanqi, AU - Shi,Yizhen, AU - Liu,Zengli, AU - Yang,Yi, Y1 - 2014/11/11/ PY - 2013/12/21/entrez PY - 2013/12/21/pubmed PY - 2015/10/8/medline KW - Cervical cancer KW - Egr-1 KW - NIS KW - Nude mouse. KW - Radionuclide therapy SP - 61 EP - 9 JF - Technology in cancer research & treatment JO - Technol. Cancer Res. Treat. VL - 14 IS - 1 N2 - The objective of this study is to explore the feasibility of radioiodine treatment for cervical cancer using the early growth response (Egr-1) promoter to control sodium-iodine symporter (hNIS) gene expression. The hNIS gene was previously transfected into Hela cells under the control of either the cytomegalovirus (CMV) or Egr-1 promoters. Na(125)I uptake was measured in the presence or absence of NaClO4. Na(125)I efflux was measured. The effects of external beam radiation on iodine uptake and retention were studied. The cytotoxic effects of (131)I were measured by clonogenic assay. The Na(125)I biodistribution was obtained using mice bearing control and transfected cells. The %ID/g of tumor and major organs were obtained for a range of times up to 48 hours post injection and the ratio of tumor to non-tumor activity (T/NT) was calculated. Tumors were imaged with Na(131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was calculated. Na(125)I uptake in Hela cells was minimal in the absence of hNIS. Uptake in the transfected cells was strong, and could be blocked by NaClO4. The iodine uptake of Hela-Egr-1-hNIS cells increased after the irradiation, and the magnitude of this effect approximately matched the radiation dose delivered. The efflux of 125I was affected by neither the promoter sequence nor pre-irradiation. (131)I reduced the clonogenic survival of symporter expressing cells, relative to the parental line. The effect was greatest in cells where hNIS was driven by the CMV promoter. Tumors formed from Hela-Egr-1-hNIS concentrated Na(125)I over a 12 hour period, in contrast to untransfected cells. These tumors could also be successfully imaged using either Na(131)I or (99m)TcO4 (-). (131)I uptake peaked at 4h, while (99m)TcO4 (-) accumulated over approximately 20 hours. In vivo uptake of (131)I and (99m)TcO4 (-) was slightly higher in cells transfected with the Egr-1 promoter, compared to CMV. Hela-Egr-1-hNIS cells demonstrate highly enhanced iodine uptake, and this effect is further augmented by radiation, creating a positive feedback loop which may bolster radionuclide therapy in vivo. SN - 1533-0338 UR - https://www.unboundmedicine.com/medline/citation/24354753/Sodium_iodine_symporter_gene_expression_controlled_by_the_EGR_1_promoter:_biodistribution_imaging_and_in_vitro_radionuclide_therapy_with_Na_131_I_ L2 - http://journals.sagepub.com/doi/full/10.7785/tcrt.2012.500396?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -